2025 Q3 -tulosraportti
77 päivää sittenTarjoustasot
Oslo Børs
Määrä
Osto
58
Myynti
Määrä
149
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 49 | - | - | ||
| 352 | - | - | ||
| 1 | - | - |
Ylin
43,795VWAP
Alin
42,5VaihtoMäärä
0,2 4 387
VWAP
Ylin
43,795Alin
42,5VaihtoMäärä
0,2 4 387
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·29.1. · MuokattuOslo, Norway, January 29, 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid tumors, today announces that the first patient has been enrolled at one of the newly activated sites in their Phase 2 study of Radspherin[®] in patients with peritoneal carcinomatosis from ovarian cancer. The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites are now open, and the first patient has been enrolled at one of these newly activated sites. "The process of opening new clinical sites involves extensive regulatory reviews, contract finalization, and site preparation work. We are therefore pleased to see both the successful activation of several sites and the enrollment of the first patient at a newly established site," said Kari Myren, Chief Medical Officer at Oncoinvent. The Phase 2 study (Clinicaltrial.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin[®] in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival (PFS) between patients receiving Radspherin[®] after complete surgical resection following preoperative chemotherapy, and patients who only receive preoperative chemotherapy and surgery. The study will recruit patients at a total of 11 sites in Norway (1), Spain (5), Belgium (1), United Kingdom (2), USA (1) and Italy (1). Positive Phase 1/2a data from the interim safety analysis showed that Radspherin[®] was well tolerated with no dose-limiting toxicity observed at the recommended dose of 7MBq.
·23.1. · MuokattuIt should be added that the issue at 52.- NOK only a few years ago was fully subscribed and this was linked to the prospectus information that the IPO would be run right after. But then it turned out that an investor grouping within the management opposed this. What happened was that they let the money drain out instead, and started trying to raise more funds at 10.- NOK, also 2.- NOK, also 50 øre, and now with a reverse split 1:100 without substantiating the newly created fall height with facts. Each time with communication that the market was not interested in the issue and that they were forced to dump the pricing. At the same time, this investor grouping increased its share with steadily lower entry costs. What was astonishing during that time also, was that the consortium bank didn't even bother to call around to all major investors to market the IPO issue that should have been carried out. Instead, it became an internal power struggle against the founder, where the share price was proactively talked down under threats of crashing the value in Onco if the founder's ideas were followed. This led to this immense expertise disappearing from the company and he created new companies instead that are now flourishing. Oncoinvent has come a long way, and as I interpret it, the remaining grouping now sits on a great treasure, but cannot carry out the crucial rapid enrollment of patients while maintaining the criteria. Personally, I believe that the company's technology has a great chance of succeeding. But the management lacks the cognitive scientific abilities to create rapid progress and the communicative talent to convince enough hospitals and doctors to refer patients. Plus, the qualitative appearance in public conveys little enthusiasm, if it is present at all. I also refer once again to my last 2 posts and encourage investors, especially small investors, to familiarize themselves with the history of the last five to 7 years, and also to get involved in the general meeting. Otherwise, one will probably soon see massive option programs for the management with further dilution. It doesn't help to constantly sit still and keep quiet, and also try to hype a stock without hardcore facts based on pure sentimentality. Everyone who tries their hand at the stock market should finally wake up and get involved. Good luck!
·26.1.100 by summer is probably a bit old news; that required them to have started the summer before. Just read the protocol, it states clearly and distinctly that they have estimated 18 months for recruitment. But yes, it was mentioned that the study should be recruited by Christmas 25 - i.e., by autumn 24. I believe and hope that recruitment will go smoothly once they get the remaining sites up and running, there are also sources to see when recruitment actually began - if that is actually the case then. Good post and hit the nail on the head. Worth remembering that those you refer to are in the same boat as us, so it remains to be seen how much the management wants to give themselves and the largest shareholder at the next crossroads. I think Hadean is thinking about how it looks on the balance sheet when the share price is down 95% since they entered. Clearly they want to push through as far as possible, so for those who believe, it's important to stick with the emissions until VIP - which hopefully will be an interim reading around Christmas time of a fully recruited study.
·22.1.There is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023- ·21.1. · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
77 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·29.1. · MuokattuOslo, Norway, January 29, 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid tumors, today announces that the first patient has been enrolled at one of the newly activated sites in their Phase 2 study of Radspherin[®] in patients with peritoneal carcinomatosis from ovarian cancer. The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites are now open, and the first patient has been enrolled at one of these newly activated sites. "The process of opening new clinical sites involves extensive regulatory reviews, contract finalization, and site preparation work. We are therefore pleased to see both the successful activation of several sites and the enrollment of the first patient at a newly established site," said Kari Myren, Chief Medical Officer at Oncoinvent. The Phase 2 study (Clinicaltrial.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin[®] in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival (PFS) between patients receiving Radspherin[®] after complete surgical resection following preoperative chemotherapy, and patients who only receive preoperative chemotherapy and surgery. The study will recruit patients at a total of 11 sites in Norway (1), Spain (5), Belgium (1), United Kingdom (2), USA (1) and Italy (1). Positive Phase 1/2a data from the interim safety analysis showed that Radspherin[®] was well tolerated with no dose-limiting toxicity observed at the recommended dose of 7MBq.
- ·23.1. · MuokattuIt should be added that the issue at 52.- NOK only a few years ago was fully subscribed and this was linked to the prospectus information that the IPO would be run right after. But then it turned out that an investor grouping within the management opposed this. What happened was that they let the money drain out instead, and started trying to raise more funds at 10.- NOK, also 2.- NOK, also 50 øre, and now with a reverse split 1:100 without substantiating the newly created fall height with facts. Each time with communication that the market was not interested in the issue and that they were forced to dump the pricing. At the same time, this investor grouping increased its share with steadily lower entry costs. What was astonishing during that time also, was that the consortium bank didn't even bother to call around to all major investors to market the IPO issue that should have been carried out. Instead, it became an internal power struggle against the founder, where the share price was proactively talked down under threats of crashing the value in Onco if the founder's ideas were followed. This led to this immense expertise disappearing from the company and he created new companies instead that are now flourishing. Oncoinvent has come a long way, and as I interpret it, the remaining grouping now sits on a great treasure, but cannot carry out the crucial rapid enrollment of patients while maintaining the criteria. Personally, I believe that the company's technology has a great chance of succeeding. But the management lacks the cognitive scientific abilities to create rapid progress and the communicative talent to convince enough hospitals and doctors to refer patients. Plus, the qualitative appearance in public conveys little enthusiasm, if it is present at all. I also refer once again to my last 2 posts and encourage investors, especially small investors, to familiarize themselves with the history of the last five to 7 years, and also to get involved in the general meeting. Otherwise, one will probably soon see massive option programs for the management with further dilution. It doesn't help to constantly sit still and keep quiet, and also try to hype a stock without hardcore facts based on pure sentimentality. Everyone who tries their hand at the stock market should finally wake up and get involved. Good luck!·26.1.100 by summer is probably a bit old news; that required them to have started the summer before. Just read the protocol, it states clearly and distinctly that they have estimated 18 months for recruitment. But yes, it was mentioned that the study should be recruited by Christmas 25 - i.e., by autumn 24. I believe and hope that recruitment will go smoothly once they get the remaining sites up and running, there are also sources to see when recruitment actually began - if that is actually the case then. Good post and hit the nail on the head. Worth remembering that those you refer to are in the same boat as us, so it remains to be seen how much the management wants to give themselves and the largest shareholder at the next crossroads. I think Hadean is thinking about how it looks on the balance sheet when the share price is down 95% since they entered. Clearly they want to push through as far as possible, so for those who believe, it's important to stick with the emissions until VIP - which hopefully will be an interim reading around Christmas time of a fully recruited study.
- ·22.1.There is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023
- ·21.1. · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
58
Myynti
Määrä
149
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 49 | - | - | ||
| 352 | - | - | ||
| 1 | - | - |
Ylin
43,795VWAP
Alin
42,5VaihtoMäärä
0,2 4 387
VWAP
Ylin
43,795Alin
42,5VaihtoMäärä
0,2 4 387
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
2025 Q3 -tulosraportti
77 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·29.1. · MuokattuOslo, Norway, January 29, 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid tumors, today announces that the first patient has been enrolled at one of the newly activated sites in their Phase 2 study of Radspherin[®] in patients with peritoneal carcinomatosis from ovarian cancer. The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites are now open, and the first patient has been enrolled at one of these newly activated sites. "The process of opening new clinical sites involves extensive regulatory reviews, contract finalization, and site preparation work. We are therefore pleased to see both the successful activation of several sites and the enrollment of the first patient at a newly established site," said Kari Myren, Chief Medical Officer at Oncoinvent. The Phase 2 study (Clinicaltrial.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin[®] in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival (PFS) between patients receiving Radspherin[®] after complete surgical resection following preoperative chemotherapy, and patients who only receive preoperative chemotherapy and surgery. The study will recruit patients at a total of 11 sites in Norway (1), Spain (5), Belgium (1), United Kingdom (2), USA (1) and Italy (1). Positive Phase 1/2a data from the interim safety analysis showed that Radspherin[®] was well tolerated with no dose-limiting toxicity observed at the recommended dose of 7MBq.
- ·23.1. · MuokattuIt should be added that the issue at 52.- NOK only a few years ago was fully subscribed and this was linked to the prospectus information that the IPO would be run right after. But then it turned out that an investor grouping within the management opposed this. What happened was that they let the money drain out instead, and started trying to raise more funds at 10.- NOK, also 2.- NOK, also 50 øre, and now with a reverse split 1:100 without substantiating the newly created fall height with facts. Each time with communication that the market was not interested in the issue and that they were forced to dump the pricing. At the same time, this investor grouping increased its share with steadily lower entry costs. What was astonishing during that time also, was that the consortium bank didn't even bother to call around to all major investors to market the IPO issue that should have been carried out. Instead, it became an internal power struggle against the founder, where the share price was proactively talked down under threats of crashing the value in Onco if the founder's ideas were followed. This led to this immense expertise disappearing from the company and he created new companies instead that are now flourishing. Oncoinvent has come a long way, and as I interpret it, the remaining grouping now sits on a great treasure, but cannot carry out the crucial rapid enrollment of patients while maintaining the criteria. Personally, I believe that the company's technology has a great chance of succeeding. But the management lacks the cognitive scientific abilities to create rapid progress and the communicative talent to convince enough hospitals and doctors to refer patients. Plus, the qualitative appearance in public conveys little enthusiasm, if it is present at all. I also refer once again to my last 2 posts and encourage investors, especially small investors, to familiarize themselves with the history of the last five to 7 years, and also to get involved in the general meeting. Otherwise, one will probably soon see massive option programs for the management with further dilution. It doesn't help to constantly sit still and keep quiet, and also try to hype a stock without hardcore facts based on pure sentimentality. Everyone who tries their hand at the stock market should finally wake up and get involved. Good luck!·26.1.100 by summer is probably a bit old news; that required them to have started the summer before. Just read the protocol, it states clearly and distinctly that they have estimated 18 months for recruitment. But yes, it was mentioned that the study should be recruited by Christmas 25 - i.e., by autumn 24. I believe and hope that recruitment will go smoothly once they get the remaining sites up and running, there are also sources to see when recruitment actually began - if that is actually the case then. Good post and hit the nail on the head. Worth remembering that those you refer to are in the same boat as us, so it remains to be seen how much the management wants to give themselves and the largest shareholder at the next crossroads. I think Hadean is thinking about how it looks on the balance sheet when the share price is down 95% since they entered. Clearly they want to push through as far as possible, so for those who believe, it's important to stick with the emissions until VIP - which hopefully will be an interim reading around Christmas time of a fully recruited study.
- ·22.1.There is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023
- ·21.1. · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
58
Myynti
Määrä
149
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 2 | - | - | ||
| 49 | - | - | ||
| 352 | - | - | ||
| 1 | - | - |
Ylin
43,795VWAP
Alin
42,5VaihtoMäärä
0,2 4 387
VWAP
Ylin
43,795Alin
42,5VaihtoMäärä
0,2 4 387
Välittäjätilasto
Dataa ei löytynyt